[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 29 of about 29
1. Weinreb I, Perez-Ordoñez B: Non-small cell neuroendocrine carcinoma of the sinonasal tract and nasopharynx. Report of 2 cases and review of the literature. Head Neck Pathol; 2007 Sep;1(1):21-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first had a tumor involving left ethmoid sinus and nasal cavity and the second, a neoplasm involving nasopharynx, sphenoid sinus, with bilateral involvement of cavernous sinuses.
  • The second is alive with locally advanced disease 7 years after radiotherapy and chemotherapy.
  • Other cases do not show specific features and are probably best regarded as "neuroendocrine carcinoma, NOS".
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Nasal Cavity / pathology. Nasopharyngeal Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology. Paranasal Sinuses / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1995 Jul;27(1):79-82 [7557912.001]
  • [Cites] Hum Pathol. 1998 Aug;29(8):826-32 [9712424.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2567-73 [15517582.001]
  • [Cites] Neurosurg Focus. 2002 May 15;12(5):e3 [16119901.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):299-306 [16163447.001]
  • [Cites] Pathol Res Pract. 1984 Jul;178(6):562-9 [6091074.001]
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1617-22 [11037813.001]
  • [Cites] Rhinology. 2001 Mar;39(1):52-4 [11340699.001]
  • [Cites] Cancer. 1980 Jan 15;45(2):330-9 [6243246.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2388-405 [7139532.001]
  • [Cites] Mod Pathol. 1995 May;8(4):421-6 [7567943.001]
  • (PMID = 20614276.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2807510
  • [Keywords] NOTNLM ; Carcinoid tumor / Nasal cavity / Neuroendocrine carcinoma / Olfactory neuroblastoma / Paranasal sinuses / Small cell carcinoma
  •  go-up   go-down


2. Gabriele AM, Airoldi M, Garzaro M, Zeverino M, Amerio S, Condello C, Trotti AB: Stage III-IV sinonasal and nasal cavity carcinoma treated with three-dimensional conformal radiotherapy. Tumori; 2008 May-Jun;94(3):320-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS AND BACKGROUND: To report the dosimetric data and clinical outcomes of patients with advanced neoplasm of the paranasal sinuses and nasal cavity, treated by three-dimensional conformal radiotherapy.
  • The primary tumor was located as follows: maxillary sinus 15 (48.4%); ethmoid sinus 10 (32.3%); nasal cavity 6 (19.3%).
  • The patients were separated in two groups according to the modality of treatment: group A included 21 patients treated with postoperative three-dimensional conformal radiotherapy with or without chemotherapy; group B included 10 patients treated with radical three-dimensional conformal radiotherapy with or without chemotherapy.
  • The median radiation dose to the planning target volume was 60 Gy (range, 56-63) for patients who underwent complete surgical resection and 68 Gy (range, 64-70) for those who did not have tumor resection or patients with residual disease.
  • Five-year local tumor control and overall survival actuarial rates were 74% and 72%, respectively, in the postoperative setting, 20% and 25%, respectively, with the primary radiotherapy.
  • No patient developed radio-induced blindness; 4 patients underwent enucleation as part of radical surgery.
  • The prognosis depends on localization, tumor stage and treatment modality.
  • [MeSH-major] Nasal Cavity. Nose Neoplasms / pathology. Nose Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / radiotherapy. Radiotherapy, Conformal
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Ethmoid Sinus. Female. Follow-Up Studies. Humans. Male. Maxillary Sinus Neoplasms / pathology. Maxillary Sinus Neoplasms / radiotherapy. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705398.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Abrahão M, Gonçalves AP, Yamashita R, Dedivitis RA, Santos RO, Nascimento LA, Mudo ML, Ferraz FA, Cervantes O: Frontal sinus adenocarcinoma. Sao Paulo Med J; 2000 Jul 6;118(4):118-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frontal sinus adenocarcinoma.
  • CONTEXT: Paranasal sinus cancer is considered rare, with an incidence of less than 1 per 100,000 per year, with the frontal sinus being the primary site in only 0.3%.
  • We report a case of adenocarcinoma arising in the frontal sinus.
  • CT scan showed a soft-tissue mass involving frontal sinus with intracranial invasion through the posterior wall.
  • The anterior ethmoid sinus and the medial aspect of the right orbit were also involved.
  • She underwent an en-bloc tumor resection by craniotomy including orbital clearance.
  • After surgery she had tumor recurrence, and chemotherapy and radiotherapy were started resulting in partial improvement.
  • [MeSH-major] Adenocarcinoma / diagnosis. Frontal Sinus. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10887389.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] BRAZIL
  •  go-up   go-down


Advertisement
4. Kajikawa H, Chatani M, Matsushiro N, Kamakura T, Kitamura T, Okumura S: [A case of advanced adenocarcinoma of the ethmoid sinus treated by chemoradiation with S-1]. Gan To Kagaku Ryoho; 2009 May;36(5):871-3
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced adenocarcinoma of the ethmoid sinus treated by chemoradiation with S-1].
  • We report a case of advanced adenocarcinoma in the left ethmoid sinus invading the frontal sinus, the frontal skull base and the orbits(T4bN0M0 and Stage IVB).
  • With the goal of functional preservation, we carried out radiation therapy with total 60 Gy irradiation and chemotherapy with S-1 80 mg/body/day before a radical operation.
  • The tumor clinically disappeared without surgical treatment, and there was no sign of recurrence for 2.5 years.
  • When we decide the treatment policy for advanced adenocarcinoma of the ethmoid sinus, chemoradiotherapy wit S-1 might be one of the effective treatments before radical operation to control the disease with preservation of functions.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ethmoid Sinus. Nose Neoplasms / drug therapy. Nose Neoplasms / radiotherapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Combined Modality Therapy. Drug Combinations. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Remission Induction. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461198.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


5. Ma AT, Lei KI: Small cell neuroendocrine carcinoma of the ethmoid sinuses presenting with generalized seizure and syndrome of inappropriate antidiuretic hormone secretion: a case report and review of literature. Am J Otolaryngol; 2009 Jan-Feb;30(1):54-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small cell neuroendocrine carcinoma of the ethmoid sinuses presenting with generalized seizure and syndrome of inappropriate antidiuretic hormone secretion: a case report and review of literature.
  • We present a case of small cell neuroendocrine carcinoma of the ethmoid sinuses associated with syndrome of inappropriate antidiuretic hormone secretion that resolved after chemotherapy, followed by a review of the literature.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology. Ethmoid Sinus / pathology. Inappropriate ADH Syndrome / etiology. Paranasal Sinus Neoplasms / pathology. Paraneoplastic Endocrine Syndromes / etiology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Neoplasm Staging. Rare Diseases

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19027514.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


6. Dulguerov P, Allal AS: Nasal and paranasal sinus carcinoma: how can we continue to make progress? Curr Opin Otolaryngol Head Neck Surg; 2006 Apr;14(2):67-72
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasal and paranasal sinus carcinoma: how can we continue to make progress?
  • PURPOSE OF REVIEW: New developments in the nasal and paranasal sinus cancers are reviewed.
  • RECENT FINDINGS: In addition to woodworking, several risk factors for nasal and paranasal sinus cancers have been identified, most notably smoking.
  • Progress in the differential diagnosis of small round cell nasal and paranasal sinus cancers allows the precise diagnosis of esthesioneuroblastoma.
  • Despite recent improvements, T staging for ethmoid and nasal cavity needs refinement.
  • An association of surgery and radiation therapy remains the best treatment modality.
  • Major developments include endoscopic resection of nasal and paranasal sinus cancers, high-precision radiotherapy techniques such as intensity-modulated radiotherapy, and proton-beam radiotherapy.
  • There is probably no role for chemotherapy in esthesioneuroblastoma.
  • Although chemotherapy is important for aggressive neoplasms, its generalized use for nasal and paranasal sinus cancers awaits the application/development of newer drugs.
  • These drugs might be applied locally since the majority of recurrences remain local.
  • SUMMARY: Progress in the treatment of nasal and paranasal sinus cancers could be achieved through better prevention and the developments of more selective treatments such as endoscopic resection, high-precision radiotherapy, and new chemotherapy drugs.
  • [MeSH-major] Carcinoma. Nasal Cavity / pathology. Nose Neoplasms. Paranasal Sinus Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552261.001).
  • [ISSN] 1068-9508
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 61
  •  go-up   go-down


7. de Tella OI Jr, Silva LR, Stavale JN, Herculano MA, de Paiva Neto MA, Agner C: Aggressive intracranial fibromatosis: case report. Arq Neuropsiquiatr; 2006 Jun;64(2B):516-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intracranial fibromatosis is extremely rare and requires aggressive treatment to prevent recurrence.
  • The lesion extended through the sphenoid, ethmoid sinus and nasal cavity, destroying the right roof of the orbit and penetrating in anterior skull base.
  • A combined anterior craniofacial approach was performed; complete resection with surgical margin was impossible due to the localization of the tumor and relation to important neurovascular structures.
  • Radiotherapy and chemotherapy are often required to improve local control of the lesion.
  • [MeSH-major] Brain Neoplasms / diagnosis. Fibromatosis, Aggressive / diagnosis
  • [MeSH-minor] Adult. Craniotomy / methods. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / surgery. Reoperation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Aggressive Fibromatosis.
  • Genetic Alliance. consumer health - Fibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917630.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


8. Padovani L, Pommier P, Clippe S S, Martel-Lafay I, Malet C, Poupart M, Zrounba P, Ceruse P, Desmes S, Carrie C, Montbarbon X, Ginestet C: Three-dimensional conformal radiotherapy for paranasal sinus carcinoma: clinical results for 25 patients. Int J Radiat Oncol Biol Phys; 2003 May 1;56(1):169-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional conformal radiotherapy for paranasal sinus carcinoma: clinical results for 25 patients.
  • PURPOSE: To assess local control, survival, and clinical and dosimetric prognostic factors in 25 patients with locally advanced maxillary or ethmoid sinus carcinoma treated by three-dimensional conformal radiotherapy (RT).
  • Seven patients received chemotherapy (concomitant with RT in four).
  • The following quality indexes were defined for the 95% and 90% isodoses: tumor conformity index, normal tissue conformity index, and global conformity index.
  • RESULTS: The median radiation dose to the planned treatment volume was 63 Gy, with a minimal dose of 60 Gy, except in 2 patients whose cancer progressed during RT.
  • After a median follow-up of 25 months, 14 local tumor recurrences developed.
  • The radiation dose and tumor conformity index value were not significant prognostic indicators.
  • Two patients died of acute infectious toxicity, and two developed late ipsilateral ocular toxicity.
  • [MeSH-major] Carcinoma / radiotherapy. Imaging, Three-Dimensional. Paranasal Sinus Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Radiation. Ethmoid Sinus. Eye Injuries / etiology. Eye Injuries / prevention & control. Female. Follow-Up Studies. Humans. Life Tables. Male. Maxillary Sinus Neoplasms / drug therapy. Maxillary Sinus Neoplasms / mortality. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Optic Nerve Injuries / etiology. Optic Nerve Injuries / prevention & control. Radiation Injuries / etiology. Radiation Injuries / prevention & control. Radiotherapy Dosage. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12694835.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Samant S, Robbins KT, Vang M, Wan J, Robertson J: Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. Arch Otolaryngol Head Neck Surg; 2004 Aug;130(8):948-55
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer.
  • OBJECTIVE: To report the long-term efficacy of a combined regimen of intra-arterial high-dose cisplatin chemotherapy and concomitant radiation therapy followed by organ-sparing surgery when possible in the treatment of advanced paranasal sinus cancer.
  • Patients Nineteen patients with advanced paranasal sinus malignancies with a minimum follow-up of 2 years.
  • Intervention Treatment consisted of preoperative radiation therapy (2.0 Gy/fraction per day; total dose, 50 Gy in 5 weeks) given concomitantly with 3 to 4 weekly infusions of intra-arterial cisplatin (150 mg/m(2) per week) and systemic sodium thiosulfate neutralization.
  • The regimen included planned surgery performed approximately 8 weeks after completion of radiation therapy.
  • One patient died of myocardial infarction during treatment.
  • No other treatment-limiting toxic effect was noted.
  • Except for cataract in 2 patients, no visual loss developed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / therapy. Carcinoma, Adenoid Cystic / therapy. Carcinoma, Squamous Cell / therapy. Cisplatin / therapeutic use. Ethmoid Sinus / pathology. Ethmoid Sinus / surgery. Maxillary Sinus / pathology. Maxillary Sinus / surgery. Paranasal Sinus Neoplasms / therapy. Radiotherapy, Computer-Assisted. Surgical Procedures, Operative
  • [MeSH-minor] Combined Modality Therapy. Disease-Free Survival. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Neoplasm Staging. Postoperative Complications / etiology. Postoperative Complications / mortality. Prospective Studies. Radiation Dosage. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Sinus cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313865.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Park KJ, Kang SH, Lee HG, Chung YG: Olfactory neuroblastoma following treatment for pituitary adenoma. J Neurooncol; 2008 Nov;90(2):237-41
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma following treatment for pituitary adenoma.
  • Olfactory neuroblastoma is extremely rare as a second neoplasm.
  • We report an unusual case of olfactory neuroblastoma in a 59-year-old woman who had undergone two operations and received 54 Gy of irradiation for pituitary adenoma 20 years ago.
  • At the time of admission, the patient presented with nasal obstruction and frequent epistaxis.
  • Imaging studies showed a large mass in the nasal cavities and ethmoid sinus, extending to the intracranial area, with no evidence of any recurrence of the previous pituitary adenoma.
  • The tumor was completely excised via a trans-cranial and trans-nasal approach.
  • A diagnosis of olfactory neuroblastoma was established, and the patient was given postoperative chemotherapy.
  • Although relatively uncommon, second neoplasms are an important consideration in the differential diagnosis of patients with new or recurring symptoms after treatment for pituitary adenoma.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3567-72 [12915637.001]
  • [Cites] Oncology. 1990;47(2):199-205 [1969134.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):800-4 [15562021.001]
  • [Cites] Arch Pathol. 1972 Jan;93(1):26-31 [5006996.001]
  • [Cites] Neurosurg Focus. 2007;23(3):E7 [17961019.001]
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2227-33 [8374881.001]
  • [Cites] J Neurosurg. 1981 Oct;55(4):615-9 [7277008.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):172-8 [9442520.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):230-9 [17047388.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):111-5 [9420081.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Oct-Nov;18(7):459-63 [11594709.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Nov;55(5):613-6 [11894972.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:69-74 [7841081.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):564-74 [1885974.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):502-12 [2204689.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):949-55 [1431959.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Neurochirurgia (Stuttg). 1993 Nov;36(6):203-6 [8309496.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):28-31 [8315464.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):854-60 [17599761.001]
  • (PMID = 18679581.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Kartha SS, Bumpous JM: Synovial cell sarcoma: diagnosis, treatment, and outcomes. Laryngoscope; 2002 Nov;112(11):1979-82
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial cell sarcoma: diagnosis, treatment, and outcomes.
  • OBJECTIVES/HYPOTHESIS: Synovial cell sarcoma is a mesenchymal tumor predominantly of the lower extremities.
  • Our experience has demonstrated aggressive behavior of this neoplasm in the head and neck.
  • METHODS: We obtained the records of patients diagnosed with head and neck synovial sarcoma from the Tumor Registry of the University of Louisville School of Medicine (Louisville, KY) and affiliated hospitals for data compiled between January 1990 and December 2000.
  • Data on patient demographics, clinical findings and symptoms, histological findings, treatment, extent of disease, recurrence, and survival were recorded.
  • All patients received chemotherapy after recurrence.
  • Four of the five patients had local recurrence, and all five of the patients developed distant metastases.
  • Novel sites are reported including the ethmoid sinus and the parotid gland.
  • The aggressive nature of the disease may require modification of accepted treatment modalities and sequence.
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Male. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12439166.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Yoshida N, Kanekura T, Hashiguchi T, Nagayama T, Hamada H, Kanzaki T: Primary squamous cell carcinoma of the frontal sinus. J Dermatol; 2006 Dec;33(12):855-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary squamous cell carcinoma of the frontal sinus.
  • We report a 74-year-old Japanese man with squamous cell carcinoma (SCC) originating in the frontal sinus.
  • Magnetic resonance imaging (MRI) revealed invasion of the anterior wall of the ethmoid sinus, the frontal bone, and possibly the meninx by a frontal sinus carcinoma.
  • Despite right fronto craniotomy with en bloc resection followed by two courses of radiation therapy and chemotherapy with 5-fluorouracil and nedaplatin or TS-1 he died of disease-related causes 20 months later.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Frontal Sinus / pathology. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Ethmoid Sinus / pathology. Facial Neoplasms / diagnosis. Fatal Outcome. Frontal Bone / pathology. Humans. Male. Neoplasm Invasiveness. Skull Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17169089.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 10
  •  go-up   go-down


13. Knott PD, Gannon FH, Thompson LD: Mesenchymal chondrosarcoma of the sinonasal tract: a clinicopathological study of 13 cases with a review of the literature. Laryngoscope; 2003 May;113(5):783-90
Genetic Alliance. consumer health - Chondrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES/HYPOTHESIS: Mesenchymal chondrosarcoma of the sinonasal tract is a rare, malignant tumor of extraskeletal origin.
  • The maxillary sinus was the most common site of involvement (n = 9), followed by the ethmoid sinuses (n = 7) and the nasal cavity (n = 5).
  • All cases were managed by surgery with adjuvant radiation therapy (n = 4) and/or chemotherapy (n = 3).
  • The overall mean survival was 12.1 years, although five of six patients who developed local recurrences died of disease (mean survival, 6.5 y).
  • CONCLUSIONS: Mesenchymal chondrosarcoma of the sinonasal tract is an aggressive tumor with a predilection for young women.
  • Aggressive, exenterative surgery combined with adjuvant therapy appears to yield the best clinical outcome.
  • [MeSH-major] Chondrosarcoma, Mesenchymal / pathology. Chondrosarcoma, Mesenchymal / radiography. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / radiography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12792311.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 30
  •  go-up   go-down


14. Cohen ZR, Marmor E, Fuller GN, DeMonte F: Misdiagnosis of olfactory neuroblastoma. Neurosurg Focus; 2002 May 15;12(5):e3
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Olfactory neuroblastoma (ON) is a rare neoplasm arising from the olfactory epithelium and found in the upper nasal cavity.
  • Based on the belief that misdiagnosis commonly occurs, they emphasized the importance of establishing the correct diagnosis, because the treatment regimens and prognosis of these tumor types are often significantly different.
  • METHODS: Twelve consecutive patients in whom ON was diagnosed were referred to the Department of Neurosurgery at the M. D.
  • Demographic data were collected, physical findings and mode of treatments were documented, and neuroimaging studies were assessed.
  • Only in two of 12 patients was the diagnosis of ON confirmed.
  • Eight of 10 patients in whom lesions were misdiagnosed required significant alteration in the initially proposed treatment plan.
  • The correct diagnosis should be ensured before initiating treatment to provide the optimum therapy and spare the patients from needless and potentially toxic treatment.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Diagnostic Errors. Esthesioneuroblastoma, Olfactory / diagnosis. Melanoma / diagnosis. Nasal Cavity. Nose Neoplasms / diagnosis. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blindness / etiology. Case Management. Cisplatin / administration & dosage. Cisplatin / adverse effects. Diagnosis, Differential. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Ethmoid Sinus / pathology. Humans. Hypopituitarism / etiology. Iatrogenic Disease. Male. Middle Aged. Paranasal Sinus Neoplasms / diagnosis. Paranasal Sinus Neoplasms / drug therapy. Paranasal Sinus Neoplasms / pathology. Radiation Injuries / etiology. Radiotherapy / adverse effects. Retrospective Studies. Sphenoid Sinus / pathology. Vincristine / administration & dosage. Vincristine / adverse effects


15. Rasp G, Kramer MF, Ostertag P, Kastenbauer E: [A new system for the classification of ethmoid polyposis. Effect of combined local and systemic steroid therapy]. Laryngorhinootologie; 2000 May;79(5):266-72
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A new system for the classification of ethmoid polyposis. Effect of combined local and systemic steroid therapy].
  • Both the medical and surgical treatment of nasal polyps present a challenge in Otorhinolaryngology.
  • METHODS: We developed a four-stage grading system for nasal polyps based on the endoscopic aspect of more than 300 patients.
  • CONCLUSIONS: Thus, we present a suitable new grading system for nasal polyps which we applied directly to assess the efficacy of combined local and systemic steroid therapy.
  • It was shown that this treatment can reduce polyps and prevent their recurrence over the observed time.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Budesonide / administration & dosage. Ethmoid Sinus. Methylprednisolone / administration & dosage. Nasal Polyps / classification. Paranasal Sinus Neoplasms / classification
  • [MeSH-minor] Administration, Intranasal. Administration, Oral. Adolescent. Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Endoscopy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10911602.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 51333-22-3 / Budesonide; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


16. Bozzo C, Stomeo F, Meloni F, Lubelli A, Profili S: About an unique case of embryocarcinoma with nasal onset. Rhinology; 2005 Jun;43(2):146-51
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both primary and salvage treatment of these tumours constitute a challenge.
  • The patient underwent 6 courses of chemotherapy and further surgery by means of an endoscopic approach, without postsurgical sequelae.
  • A 5-years follow-up, with periodic controls, laboratory tests and imaging, all without signs of recurrence, confirmed that this unusual location of EC responded exclusively to primary chemotherapy, while earlier studies proved EC being responsive, in other sites of onset, to a combination of chemotherapy, radical surgical excision of the neoplasm, and radiotherapy.
  • [MeSH-major] Carcinoma, Embryonal / diagnosis. Nose Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Endoscopy. Ethmoid Sinus / surgery. Follow-Up Studies. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008073.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


17. Hanna E, DeMonte F, Ibrahim S, Roberts D, Levine N, Kupferman M: Endoscopic resection of sinonasal cancers with and without craniotomy: oncologic results. Arch Otolaryngol Head Neck Surg; 2009 Dec;135(12):1219-24
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS: All patients with biopsy-proved malignant neoplasm of the sinonasal region who were treated with endoscopic resection between 1992 and 2007 were included in the study, and their charts were reviewed for demographics, histopathologic findings, treatment details, and outcome.
  • Of the 120 patients, 41% presented with previously untreated disease, 46% presented with persistent disease that had been partially resected, and 13% presented with recurrent disease after prior treatment.
  • The most common site of tumor origin was the nasal cavity (52%), followed by the ethmoid sinuses (28%).
  • However, the T-stage distribution was significantly different between the EEA group and the CEA group.
  • The most common tumor types were esthesioneuroblastoma (17%), sarcoma (15%), adenocarcinoma (14%), melanoma (14%), and squamous cell carcinoma (13%).
  • Of the 120 patients, 50% were treated with surgery alone, 37% received postoperative radiation therapy, and 13% were treated with surgery, radiation therapy, and chemotherapy.
  • Our results suggest that, in well-selected patients and with appropriate use of adjuvant therapy, endoscopic resection of sinonasal cancer results in acceptable oncologic outcomes.
  • [MeSH-major] Endoscopy. Paranasal Sinus Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / surgery. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Child. Craniotomy. Disease-Free Survival. Esthesioneuroblastoma, Olfactory / surgery. Ethmoid Sinus. Female. Humans. Male. Melanoma / surgery. Middle Aged. Neoplasm Recurrence, Local. Nose Neoplasms / mortality. Nose Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026819.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Katz TS, Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW, Villaret DB: Malignant tumors of the nasal cavity and paranasal sinuses. Head Neck; 2002 Sep;24(9):821-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the role of radiation therapy in patients with nasal cavity and paranasal sinus tumors.
  • MATERIALS AND METHODS: Between October 1964 and July 1998, 78 patients with malignant tumors of the nasal cavity (48 patients), ethmoid sinus (24 patients), sphenoid sinus (5 patients), or frontal sinus (1 patient) were treated with curative intent by radiation therapy alone or in the adjuvant setting.
  • Forty-seven patients were treated with irradiation alone, 25 with surgery and postoperative irradiation, 2 with preoperative irradiation and surgery, and 4 with chemotherapy in combination with irradiation with or without surgery.
  • Of the 67 (86%) patients who were initially seen with node-negative disease, 39 (58%) received no elective neck treatment, and 28 (42%) received elective neck irradiation.
  • Of the 39 patients who received no elective neck treatment, 33 (85%) did not experience recurrence in the neck compared with 25 (89%) of 28 patients who received elective neck irradiation.
  • CONCLUSION: Surgery and postoperative radiation therapy may result in improved local control, absolute survival, and complications when compared with radiation therapy alone.
  • [MeSH-major] Carcinoma / therapy. Nasal Cavity. Nose Neoplasms / therapy. Paranasal Sinus Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Blindness / etiology. Blindness / prevention & control. Cause of Death. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Osteoradionecrosis / etiology. Postoperative Care. Preoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant / adverse effects. Risk Factors. Survival Rate. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley Periodicals, Inc. Head Neck 24: 821-829, 2002
  • (PMID = 12211046.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Rombaux P, De Toeuf C, Hamoir M, Eloy P, Bertrand B: [Sinus-nasal polyposis: one-year outcome after endoscopic sinus surgery followed by topical corticosteroid therapy in 72 patients]. Ann Otolaryngol Chir Cervicofac; 2001 Oct;118(5):291-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sinus-nasal polyposis: one-year outcome after endoscopic sinus surgery followed by topical corticosteroid therapy in 72 patients].
  • [Transliterated title] La polypose naso-sinusienne. Résultats à un an de la chirurgie endoscopique endosinusienne suivie d'une corticothérapie topique chez 72 patients.
  • Nasal polyposis (NP) is considered as an inflammatory disease for which first line therapy is topical and/or oral corticosteroid.
  • In this paper we attempted to determine the efficacy of endoscopic endonasal surgery followed by topical corticoid in 72 adults suffering from bilateral NP refractory to corticosteroid therapy and to delineate the clinical characteristics of this cohort of patients.
  • NP was confirmed endoscopically and with computed tomography.
  • Topical corticoid therapy was started 2 months after surgery.
  • Anterior and posterior ethmoid sinus and maxillary sinus were the most affected sinuses.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Methylprednisolone / administration & dosage. Nasal Polyps / drug therapy. Nasal Polyps / surgery. Paranasal Sinuses
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Combined Modality Therapy. Endoscopy. Female. Follow-Up Studies. Glucocorticoids. Humans. Male. Middle Aged. Neoplasm Staging. Severity of Illness Index. Time Factors

  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11845037.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Glucocorticoids; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


20. Paiva MB, Bublik M, Castro DJ, Udewitz M, Wang MB, Kowalski LP, Sercarz J: Intratumor injections of cisplatin and laser thermal therapy for palliative treatment of recurrent cancer. Photomed Laser Surg; 2005 Dec;23(6):531-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumor injections of cisplatin and laser thermal therapy for palliative treatment of recurrent cancer.
  • OBJECTIVE: The aim of this work was to report initial findings on the clinical application of intratumor injection of cisplatin in a gel (CDDP/gel) combined with laser-induced thermal therapy (LITT) for cancer treatment in a single patient with advanced stage disease.
  • BACKGROUND DATA: LITT with the neodymium:yttriumaluminum- garnet (Nd:YAG) laser via fiberoptics is a precise, minimally invasive alternative for thermoablation of unresectable or recurrent head and neck neoplasms, but recurrence is often seen at the treatment margins.
  • Combining intratumor chemotherapy with interstitial laser should be most effective using drugs with thermally enhanced toxicity, such as cisplatin.
  • The CDDP/gel therapeutic implant was expected to retain a higher concentration of cisplatin in the tumor margins for improved LITT treatment of the patient presented.
  • METHODS: In this case report, the cisplatin dose was 0.25 mL gel/cm(3) tumor volume (20 mg of CDDP) followed by LITT (Nd:YAG laser, 50 W, PD = 2,200 J/cm(2)) after the chemotherapy session.
  • RESULTS: The patient responded with local tumor eradication, and no signs of systemic toxicity were observed related to this therapy.
  • However, the patient developed progressive metastatic disease in the lungs and died 2.5 months later.
  • CONCLUSIONS: This is a report of a patient with an accessible solid tumor who was treated with intratumor injection of CDDP/gel followed by LITT, which proved to be feasible.
  • Based on preclinical evidence obtained at UCLA and the results of this study, we are encouraged to continue our refinement of LITT combined with chemotherapy for cancer treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Laser Therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Aged. Ethmoid Sinus. Female. Fiber Optic Technology. Humans. Injections, Intralesional. Melanoma / therapy. Palliative Care. Paranasal Sinus Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356142.001).
  • [ISSN] 1549-5418
  • [Journal-full-title] Photomedicine and laser surgery
  • [ISO-abbreviation] Photomed Laser Surg
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA 88921
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


21. Esposito F, Kelly DF, Vinters HV, DeSalles AA, Sercarz J, Gorgulhos AA: Primary sphenoid sinus neoplasms: a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies. J Neurooncol; 2006 Feb;76(3):299-306
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sphenoid sinus neoplasms: a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies.
  • BACKGROUND: Primary neoplasms of the sphenoid sinus are a rare occurrence, accounting for approximately 1-2% of all paranasal sinus tumors.
  • METHODS: Four patients with sphenoid sinus neoplasms were identified (1%), all treated during the year 2003.
  • MRIs in all patients demonstrated large sphenoid sinus masses with partial clival and sellar bone erosion but with clear visualization of the pituitary gland above the mass.
  • Cavernous sinus invasion was present in all four cases, including one patient with tumor in the ethmoid sinus and intra-tumoral hemorrhage.
  • All patients underwent subtotal tumor removal via an endonasal transsphenoidal route.
  • Tumor histology included neuroendocrine carcinoma, sinonasal undifferentiated carcinoma, mucoepidermoid carcinoma, and giant cell tumor.
  • Metastatic work-ups were negative in all patients, and all received fractionated stereotactic radiotherapy; three received chemotherapy.
  • One patient required a second endonasal tumor debulking 15 months after the first for new visual loss that then resolved.
  • In this small series, they presented with cavernous sinus symptoms and headache but not endocrinopathy.
  • Their aggressive nature warrants a multimodality treatment plan including surgical debulking, radiotherapy, and chemotherapy in some cases.
  • [MeSH-major] Neurosurgical Procedures. Paranasal Sinus Neoplasms / pathology. Paranasal Sinus Neoplasms / therapy. Sphenoid Sinus / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / metabolism. Carcinoma / pathology. Carcinoma / therapy. Carcinoma, Giant Cell / metabolism. Carcinoma, Giant Cell / pathology. Carcinoma, Giant Cell / therapy. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / therapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2002 Sep;51(3):699-705; discussion 705-7 [12188948.001]
  • [Cites] Head Neck Surg. 1984 Jan-Feb;6(3):761-76 [6319335.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):371-6 [11859210.001]
  • [Cites] Laryngoscope. 1989 Jul;99(7 Pt 1):716-20 [2747395.001]
  • [Cites] Laryngoscope. 1963 May;73:537-46 [14011951.001]
  • [Cites] Cephalalgia. 1988 Dec;8(4):229-36 [3219724.001]
  • [Cites] Laryngoscope. 1997 Dec;107(12 Pt 1):1590-5 [9396670.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14 (1):11-22 [3335447.001]
  • [Cites] Yonsei Med J. 1988;29(3):209-18 [3057747.001]
  • [Cites] Head Neck. 1996 Mar-Apr;18(2):160-5; discussion 166 [8647682.001]
  • [Cites] Neurosurgery. 1993 Oct;33(4):602-8; discussion 608-9 [8232799.001]
  • [Cites] J Neurosurg. 1981 Aug;55(2):187-93 [7252541.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1179-87 [12973841.001]
  • [Cites] Laryngoscope. 1973 Aug;83(8):1252-65 [4758128.001]
  • [Cites] Pituitary. 2002;5(4):261-5 [14558675.001]
  • [Cites] World J Surg. 2003 Jul;27(7):849-55 [14509518.001]
  • [Cites] Minim Invasive Neurosurg. 1998 Jun;41(2):66-73 [9651913.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):663-72 [12152781.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):581-9 [1503031.001]
  • [Cites] J Otolaryngol. 1978 Oct;7(5):379-88 [105151.001]
  • [Cites] Arch Otolaryngol. 1978 Oct;104(10):585-7 [697636.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Jul;122(7):765-8 [8663951.001]
  • [Cites] Neurosurgery. 2000 May;46(5):1084-91; discussion 1091-2 [10807240.001]
  • [Cites] Otolaryngol Head Neck Surg. 1990 Jun;102(6):709-16 [2115658.001]
  • [Cites] Eur J Pediatr. 1996 Aug;155(8):717-9 [8839732.001]
  • [Cites] J Otolaryngol. 1990 Apr;19(2):122-9 [2348505.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • [Cites] Head Neck. 1991 May-Jun;13(3):208-12 [2037472.001]
  • [Cites] Med J Aust. 2000 Nov 20;173(10):548-9 [11194741.001]
  • [Cites] Neuroradiology. 1998 Oct;40(10 ):651-5 [9833894.001]
  • [Cites] Brain. 1984 Sep;107 ( Pt 3):855-70 [6478180.001]
  • [Cites] J Craniofac Surg. 1995 Jan;6(1):15-23 [8601000.001]
  • [Cites] J Neurosurg Sci. 1999 Mar;43(1):25-36 [10494663.001]
  • [Cites] Head Neck. 2002 Sep;24(9):821-9 [12211046.001]
  • [Cites] Br J Neurosurg. 1994;8(1):51-5 [8011194.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 May;259(5):266-8 [12107531.001]
  • [Cites] Am J Otolaryngol. 1995 Mar-Apr;16(2):109-14 [7793504.001]
  • [Cites] J Neurosurg. 2003 Feb;98(2):350-8 [12593622.001]
  • [Cites] Pathology (Phila). 1996;3(2):513-34 [8795833.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Jan;120(1):19-25 [8274251.001]
  • [Cites] Am J Emerg Med. 2001 Jan;19(1):88-90 [11146033.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):913-5; discussion 915-6 [9574657.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):367-72 [12598339.001]
  • [Cites] Neurosurgery. 2003 Nov;53(5):1126-35; discussion 1135-7 [14580279.001]
  • [Cites] Cancer. 1977 Dec;40(6):3038-41 [412586.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):1964-9 [12439163.001]
  • [Cites] J Laryngol Otol. 1995 Oct;109(10):951-5 [7499947.001]
  • (PMID = 16163447.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Velche-Haag B, Dehesdin D, Proust F, Marie JP, Andrieu-Guitrancourt J, Laquerriere A: [Ewing's sarcoma of the head and neck: a case report]. Ann Otolaryngol Chir Cervicofac; 2002 Dec;119(6):363-8
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of Ewing's sarcoma located in the ethmoid sinus.
  • Diagnosis was established at microscopic examination with histoimmunochemistry and molecular biology.
  • Treatment combined chemotherapy and surgical resection with skull base reconstruction and post-operative ratio and chemotherapy.
  • [MeSH-major] Bone Neoplasms / therapy. Ethmoid Sinus / surgery. Sarcoma, Ewing / therapy
  • [MeSH-minor] Adult. Antibodies, Neoplasm / immunology. Antigens, CD / immunology. Cell Adhesion Molecules / immunology. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12527847.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  •  go-up   go-down


23. Hallacq P, Labrousse F, Roullet B, Orsel S, Bessede JP, Moreau JJ: [Adenoid cystic carcinomas invading the skull base. Apropos of 4 cases and review of the literature]. Neurochirurgie; 2001 Dec;47(6):542-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Carcinomes adénoïdes kystiques envahissant la base du crâne. A propos de 4 observations et revue de la littérature.
  • Neurosurgical decision making is not well defined regarding the extent of intracranial tumor component removal, as neurosurgical expertise is limited for this peculiar type of tumors.
  • Over a 13-year period, four adenoid cystic carcinomas invading the skull base were operated on at our institution: two tumors originated in the parotid gland, one in the sphenoid sinus, and one in the ethmoid sinus.
  • One patient with advanced metastatic disease was submitted to chemotherapy.
  • Three patients died from local tumor progression and distant metastases within three years after the intracranial tumor extension has been diagnosed.
  • The patient with an ethmoid tumor is still alive seven years after surgery without any evidence of local tumor progression nor distant metastases.
  • Surgery remains the gold standard treatment for adenoid cystic carcinomas invading the skull base.
  • However, in our opinion a large tumor removal, without or with bone osteotomies, but without sacrifice of cranial nerves, cavernous sinus, internal carotid artery, and of the orbit allows patient survival with an acceptable comfort and absence of psychological distress due to disfigurating surgery nor surgically induced neurological functional deficit.
  • The place of chemotherapy has, yet, to be determined.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Ethmoid Sinus / surgery. Paranasal Sinus Neoplasms / surgery. Parotid Neoplasms / surgery. Skull Base Neoplasms / surgery. Sphenoid Sinus / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Invasiveness. Radiotherapy, Adjuvant

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11915613.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


24. Yamamoto R, Hosokawa S, Yamatodani T, Morita S, Okamura J, Mineta H: [Eight cases of neuroendcrine carcinoma of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jul;111(7):517-22
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small cell neuroendocrine carcinoma of the head and neck is rare, and diagnosis may be difficult.
  • Three cases arose from the maxillary sinus, two from the ethmoid sinus, one from the parotid gland, one from the tonsil, and one from the larynx.
  • Histological analysis by hematoxylin-eosin staining tentatively revealed malignant lymphoma and undifferentiated carcinoma in two cases each, while immunohistological and/or electron microscopy analysis confirmed histological diagnosis.
  • All were treated by chemotherapy (VP-16, CDDP) and seven cases with radiotherapy based on the schedule of small cell carcinoma of the lung and two cases with lesional resection.
  • Chemotherapy and radiotherapy were effective locally.
  • Long-term survival thus requires the effective treatment of distant metastasis.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Epirubicin / administration & dosage. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697475.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; PE regimen
  •  go-up   go-down


25. Pomar Blanco P, San Román Carbajo J, Bouso Montero M, Martín Villares C, Fernández Pello M, Tapia Risueño M: [Sinonasal mucosal melanoma]. An Otorrinolaringol Ibero Am; 2007;34(4):349-58
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis may require confirmatory immunohistochemical stains (S-100 protein, HMB-45, vimentin and cytokeratine).
  • The clinical records of 6 patients with the diagnosis of sinonasal melanomas between 1991 and 2005 were retrospectively reviewed.
  • Surgery was performed in four patients, adjuvant radiation therapy was used in one patient after local recurrence and chemotherapy in three patients.
  • Three of four patients (75%) had a recurrence after previous treatment (surgery).
  • [MeSH-major] Ethmoid Sinus. Maxillary Sinus Neoplasms. Melanoma. Nasal Cavity. Nasal Mucosa. Nose Neoplasms. Paranasal Sinus Neoplasms
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Positron-Emission Tomography. Prognosis. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17844954.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


26. Park KA, Oh SY: Nasopharyngeal carcinoma presenting with rapidly progressive severe binocular optic neuropathy and periocular pain in a young man. J Neuroophthalmol; 2010 Jun;30(2):150-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For a presumptive diagnosis of retrobulbar optic neuritis, he was treated with intravenous corticosteroids, and vision improved transiently.
  • Nasopharyngoscopy disclosed a soft tissue lesion filling the apex of the nasopharynx and the posterior portion of the ethmoid sinus with associated sinusitis.
  • [MeSH-minor] Adult. Blindness / etiology. Diagnosis, Differential. Diagnostic Errors / prevention & control. Disease Progression. Drug Therapy. Dura Mater / pathology. Ethmoid Sinus / pathology. Eye / physiopathology. Humans. Magnetic Resonance Imaging. Male. Nasopharynx / pathology. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Optic Nerve / pathology. Optic Nerve / physiopathology. Sella Turcica / pathology. Skull Base Neoplasms / secondary. Sphenoid Bone / pathology. Time Factors. Vision, Low / etiology

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414132.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Chen AM, Daly ME, El-Sayed I, Garcia J, Lee NY, Bucci MK, Kaplan MJ: Patterns of failure after combined-modality approaches incorporating radiotherapy for sinonasal undifferentiated carcinoma of the head and neck. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):338-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary tumor sites included the nasal cavity (11 patients), maxillary sinus (5 patients), and ethmoid sinus (5 patients).
  • Local-regional treatment included surgery followed by postoperative radiotherapy (PORT) with or without adjuvant chemotherapy for 17 patients; neoadjuvant chemoradiotherapy followed by surgery for 2 patients; and definitive chemoradiotherapy for 2 patients.
  • There was no difference in local control according to initial treatment approach, but among the 19 patients who underwent surgery the 5-year local control rate was 74% for those with gross tumor resection, compared with 24% for those with subtotal tumor resection (p = 0.001).
  • CONCLUSION: The suboptimal outcomes suggest a need for more effective therapies.
  • Gross total resection should be the goal of all treatments whenever possible.
  • [MeSH-major] Carcinoma / therapy. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant / methods. Combined Modality Therapy / methods. Ethmoid Sinus. Female. Follow-Up Studies. Humans. Male. Maxillary Sinus Neoplasms / mortality. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / therapy. Middle Aged. Neoadjuvant Therapy / methods. Neoplasm Recurrence, Local. Paranasal Sinus Neoplasms / mortality. Paranasal Sinus Neoplasms / radiotherapy. Paranasal Sinus Neoplasms / therapy. Radiotherapy, Adjuvant / methods. Remission Induction. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Sinonasal undifferentiated carcinoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207030.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Lu TX, Mai WY, Teh BS, Zhao C, Han F, Huang Y, Deng XW, Lu LX, Huang SM, Zeng ZF, Lin CG, Lu HH, Chiu JK, Carpenter LS, Grant WH 3rd, Woo SY, Cui NJ, Butler EB: Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys; 2004 Mar 1;58(3):682-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To report our initial experience on the feasibility, toxicity, and tumor control using intensity-modulated radiotherapy (IMRT) for retreatment of recurrent nasopharyngeal carcinoma (NPC).
  • The average time to the nasopharyngeal recurrence was 30.2 months after initial conventional RT.
  • The median isocenter dose to the nasopharynx was 70 Gy (range 60.9-78.0) for the initial conventional RT.
  • All patients were restaged at the time of recurrence according to the 1992 Fuzhou, China staging system on NPC.
  • Invasion of the nasal cavity, maxillary sinus, ethmoid sinus, sphenoid sinus, and cavernous sinus and erosion of the base of the skull was found in 8, 1, 3, 8, 15, and 20 patients, respectively.
  • The gross tumor volume (GTV) was contoured according to the International Commission on Radiation Units and Measurements (ICRU) Report 62 guidelines.
  • The GTV in the nasopharynx and positive lymph nodes in the neck received a prescription dose of 68-70 Gy and 60 Gy, respectively.
  • Three patients who had positive lymph nodes were treated with five to six courses of chemotherapy (cisplatin + 5-fluorouracil) after IMRT.
  • RESULTS: The treatment plans showed that the percentage of GTV receiving 95% of the prescribed dose (V(95-GTV)) was 98.5%, and the dose encompassing 95% of GTV (D(95-GTV)) was 68.1 Gy in the nasopharynx.
  • The mean dose to the GTV was 71.4 Gy.
  • Three patients developed metastases at a distant site: two in the bone and one in the liver and lung at 13 months follow-up.
  • Acute toxicity (skin, mucosa, and xerostomia) was acceptable according to the Radiation Therapy Oncology Group criteria.
  • Tumor necrosis was seen toward the end of IMRT in 14 patients (28.6%).
  • CONCLUSION: The improvement in tumor target coverage and significant sparing of adjacent critical structures allow the feasibility of IMRT as a retreatment option for recurrent NPC after initial conventional RT.
  • The treatment-related toxicity profile was acceptable.
  • The initial tumor response/local control was also very encouraging.
  • In contrast to primary NPC, recurrent NPC reirradiated with high-dose IMRT led to the shedding of tumor necrotic tissue toward the end of RT.
  • More patients and longer term follow-up are warranted to evaluate late toxicity and treatment outcome.
  • [MeSH-major] Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Radiotherapy, Conformal / methods

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14967420.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Su ZY, Zhang DS, Zhu MQ, Shi YX, Jiang WQ: [Primary non-Hodgkin's lymphoma of the paranasal sinuses: a report of 14 cases]. Ai Zheng; 2007 Aug;26(8):919-22
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Primary paranasal sinus lymphoma (PPSL) is a rare presentation of extranodal non-Hodgkin's lymphoma with a natural history distinct from other lymphomas.
  • This study was to evaluate the clinical and pathologic characteristics, treatment outcomes and prognosis of PPSL.
  • RESULTS: The primary involvement sites included the maxillary sinus (11 cases), ethmoid sinus (2 cases), and sphenoid sinus (1 case).
  • The most common type was diffuse large B-cell PPSL (6 cases, 42.9%).
  • All patients received chemotherapy and 6 received radiotherapy after chemotherapy.
  • Diffuse large B-cell lymphoma is the most common histologic type and the maxillary sinus is the most common original site of PPSL.
  • A combined-modality approach with systemic chemotherapy and local-regional radiation is recommended for PPSL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Paranasal Sinus Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Follow-Up Studies. Humans. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Lymphoma, T-Cell / surgery. Maxillary Sinus / surgery. Middle Aged. Neoplasm Staging. Paranasal Sinuses / pathology. Prednisone / therapeutic use. Remission Induction. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17697560.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down






Advertisement